Thyroid Eye Disease Gains an At-Home Injection Option: FDA Approves Enspryng, With Mixed Results Across Two Trials
Maintenance treatment every four weeks could give some patients an opportunity to reduce trips to infusion centers. Beyond convenience, however, one pivotal trial missed its primary endpoint, while comparative efficacy and monitoring at home remain unresolved.